New pathogen for gastric cancer: Streptococcus anginosus

References

[1] Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016; 19(1): 166-175.

[2] Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020; 158(3): 527-536.e7.

[3] Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018; 67(6): 1024-1032.

[4] Sung JJY, Coker OO, Chu E, et al. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 2020; 69(9): 1572-1580.

[5] Fu K, Cheung AHK, Wong CC, et al. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell. 2024; 187(4): 882-896.e17.

[6] Terzi HA, Demiray T, Koroglu M, et al. Intra-abdominal abscess and primary peritonitis caused by Streptococcus anginosus. Jundishapur J Microbiol. 2016; 9(6): e33863.

[7] Xiao X, Zhang X, Wang J, et al. Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study. Gut. 2024; 73(7): 1098-1109.

[8] Zeng R, Sha W, Wang J, et al. Evaluation of proton pump inhibitors and risks of gastric cancer. Gut. 2022; 71(9): 1924-1926.

[9] Knoop KA, McDonald KG, Kulkarni DH, Newberry RD. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut. 2016; 65(7): 1100-1109.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.